Kenya has joined the global clinical trial of Oxford University’s COVID-19 vaccine candidate, ChAdOx1 nCoV-19, as reported National Post on Friday.
The vaccine has been developed jointly with AstraZeneca and is also being evaluated in Britain, South Africa and Brazil.
"To ensure that Kenyans can benefit… if it proves to be successful, it is important to assess its performance among Kenyan volunteers," said the Kenya Medical Research Institute (KEMRI).
KEMRI added that it has already vaccinated the first volunteers after receiving the required regulatory and ethical approvals.
The study in Kenya will initially involve 40 frontline workers and an additional 360 volunteers will also be recruited if initial phase ascertains the vaccine's safety.
To read more NewsPoints articles, click here.